ABSTRACT
Parietal metastasis is a very rare secondary location of papillary thyroid carcinoma. It associated with poor prognosis. We report a case of a 61-year-old woman with parietal metastasis from papillary thyroid carcinoma. The patient presented a parietal nodule on the back. In her past history, she had been diagnosed papillary thyroid carcinoma after total thyroidectomy and also reoperated for local recurrence. The CT scan performed has revealed metastasis to the lungs, bones, lymph nodes and adrenal glands. The parietal nodule was excised and submitted for histopathological examination. The histologic and immunohistochemical findings confirmed the thyroid origin. Although papillary thyroid carcinoma is a relatively indolent tumour, it can exhibit an unusual metastatic behaviour.
Subject(s)
Thyroid Neoplasms , Thyroidectomy , Female , Humans , Lymph Nodes , Middle Aged , Thyroid Cancer, Papillary , Thyroid Neoplasms/diagnosis , Thyroid Neoplasms/surgeryABSTRACT
BACKGROUND: The promoter region is a key element of gene expression regulation. In mammals, most of the genes present, at the level of their promoter, a large number of islands CpG. Age also is seen as another factor for developing breast cell cancer reaching the tumour stage. AIM: This study aimed to explore the hypermethylation of the BRCA1/2 promoter gene in women breast cancer and correlation with age and tumour stage. MATERIALS AND METHODS: Fifty biopsies were derived from Moroccan women treated for breast carcinoma, the DNA extracted was treated by bisulphite and the targeted BRCA1/2 Amplicons were amplified by specific methylation primers (MSP). RESULTS: The result shows that 62% of the samples were BRCA1 methylated in addition and negative result for BRCA2, these positive epigenetic factor were remarkable in women over 47 years and at the stage of malignant tumour. CONCLUSION: These results show that half of the methylated samples are positive with a majority of over 47 years old, and confirms that age might be an additional factor for breast cancer development.